Delcath Systems Inc Aktie News

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: Craig-Hallum Alpha Select Conference on Tuesday, November 18, 2025, in New York, NY Canaccord Genuity MedTech, Diagnostics and Dig...

Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time.

Delcath Systems, Inc. ( DCTH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO & Director Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Marie Thibault - BTIG, LLC, Research Division John Newman - Canaccord Ge...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Total revenue of $20.6 million, compared with $11.2...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2025. Conference Call Information To participate in this event,...

Delcath Systems, Inc. (NASDAQ:DCTH ) Discusses CHOPIN Trial Results and Preliminary Q3 Financials October 20, 2025 8:45 AM EDT Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO & Director Vojislav Vukovic - Chief Medical Officer Sandra Pennell - Chief Financial Officer Conference Call Participants Vincent T. Ma Marie Thibaul...

Delcath offers a liver-directed chemotherapy system, which is currently used to treat metastatic uveal melanoma patients. Delcath is facing pricing pressure and slow hospital onboarding at the moment, adding to concerns about the size of the company's addressable market. Recent clinical data support PHP's efficacy in combination with immunotherapies, potentially broadening adoption and addressi...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance. Preliminary Third Quarter Financial Results (unaudited) Total CHEMOSAT and HEPZ...